Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report

Cerebrospinal Fluid Concentration of the RET Inhibitor Pralsetinib: A Case Report

Introduction: Pralsetinib is used to treat metastatic RET fusion-positive non-small cell lung cancer. Preclinical studies of pralsetinib have shown blood-brain barrier (BBB) penetration and intracranial activity. The intracranial efficacy of pralsetinib in patients with brain metastasis is considere...

Full description

Bibliographic Details
Main Authors: Loek A.W. De Jong, Rolf W. Sparidans, Michel M. van den Heuvel
Format: Article
Language:English
Published: Karger Publishers 2023-12-01
Series:Case Reports in Oncology
Subjects:
pralsetinib
cerebrospinal fluid
lung cancer
brain metastasis
case report
Online Access:https://beta.karger.com/Article/FullText/535172

Internet

https://beta.karger.com/Article/FullText/535172

Similar Items